Drugs & Targets

Drugs & Targets

FDA Grants Priority Review to Atezolizumab

FDA granted Priority Review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of people with locally advanced or metastatic urothelial carcinoma who had disease progression during or following platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of receiving platinum-based chemotherapy before or after surgery. “Atezolizumab was granted Priority Review designation based... […]
Drugs & Targets

FDA Grants Orphan Designation to VAL-083

FDA granted an Orphan Drug Designation to VAL-083 for the treatment of medulloblastoma. The investigational drug candidate, developed by DelMar Pharmaceuticals Inc., previously received an orphan designation for glioblastoma in the U.S. and in Europe. VAL-083 is a first-in-class chemotherapeutic. In more than 40 phase I and II clinical studies sponsored by the NCI, VAL-083... […]
Drugs & Targets

China Food and Drug Administration Approves CINtec PLUS Cytology Test

The China Food and Drug Administration approved the CINtec PLUS Cytology test, developed by Roche, for identifying women with cervical pre-cancer. A multi-center study of five participating hospitals throughout China revealed greater overall performance of combined sensitivity and specificity of the CINtec PLUS Cytology test in determining which women are at higher risk of developing... […]
Drugs & Targets

Regulatory Authorities in Six Countries approve Yondelis

Regulatory authorities in six countries have granted 10 sales authorizations for Yondelis. Five of those authorizations are for Yondelis (trabectedin) in combination with Caelyx (pegylated liposomal doxorubicin) for treating relapsed platinum-sensitive ovarian cancer, in Bangladesh, Costa Rica, Kuwait, Moldavia and Saudi Arabia The other five authorizations are for Yondelis for soft tissue sarcoma, in Bangladesh,... […]
Drugs & Targets

Veritas Genetics introduces whole genome platform for under $1,000

Veritas Genetics introduced Veritas myGenome, a whole genome sequencing platform for less than $1,000, including interpretation and genetic counseling. The platform includes a digital report and app to interact with results, on-demand additional genetic counseling via video conferencing, and lifestyle-relevant genetic information that can be shared with non-clinical service providers such as fitness coaches and... […]
Drugs & Targets

NanoString Technologies and Merck to collaborate on Keytruda assay

NanoString Technologies Inc. entered into a collaboration agreement with Merck, through a subsidiary, to develop and commercialize a novel diagnostic assay to predict response to Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy. Under the terms of the collaboration agreement, NanoString will be responsible for seeking regulatory approval for and commercialization of the diagnostic test. NanoString will be... […]